The Truth About Spravato (esketamine): Profits before patients

1. The Weight of Evidence for Ketamine

Ketamine has long been recognized for its rapidly acting antidepressant effects in TRD. Over the past two decades, a robust body of research has focused on IV ketamine, rather than intranasal esketamine, to understand its efficacy and mechanism. Early landmark studies demonstrated that IV ketamine could reduce depressive symptoms within hours—far faster than typical antidepressants that often take weeks to produce measurable effects. [1][2]

Subsequent clinical trials expanded on this initial promise. Researchers observed that a single IV ketamine infusion led to clinically significant improvements in mood and, in some patients, partial or full remission from depressive symptoms that lasted anywhere from days to weeks. This immediate and profound response has spurred ongoing investigations into maintenance or repeated infusion protocols to sustain these beneficial effects.

Additional Evidence for Ketamine

Beyond anecdotal success stories, numerous systematic reviews and meta-analyses have underscored ketamine’s efficacy. For example, aggregated data reveal not only significant short-term antidepressant effects but also the potential for rapid alleviation of suicidal ideation. In many studies, the rate and magnitude of symptom improvement with IV ketamine outpace those seen in standard pharmacological treatments. [3][4]

The precise reasons for ketamine’s effectiveness remain under investigation. Evidence points to ketamine’s antagonistic activity at the NMDA receptor, which modulates glutamate—the most abundant excitatory neurotransmitter in the brain. However, researchers are increasingly exploring additional mechanisms beyond NMDA receptor antagonism. These include its role in promoting the release of brain-derived neurotrophic factor (BDNF), enhancing synaptic plasticity, and modulating inflammatory pathways. Furthermore, arketamine, the less-studied enantiomer of ketamine, has been shown to have independent antidepressant effects that may be mediated through the AMPA receptor, further underscoring the complexity of ketamine’s mechanisms. This multifaceted activity may instigate neuroplastic changes that help reset disrupted brain networks associated with depression, offering a more holistic understanding of its antidepressant effects. [14]

2. IV Ketamine’s Efficacy

Because IV ketamine has the longest track record, its administration protocols and safety considerations are relatively well-known. Meta-analyses and systematic reviews confirm that IV ketamine provides robust antidepressant effects for TRD, with benefits often persisting for days or weeks after just one dose. Repeated dosing, sometimes referred to as “ketamine maintenance,” has been explored in multiple studies, showing promise for extending these rapid benefits. [3][4]

Moreover, IV ketamine is flexible in dosing strategies and can be carefully titrated by experienced clinicians. Many ketamine infusion clinics have protocols in place to monitor blood pressure, dissociative symptoms, and overall patient well-being, ensuring a controlled delivery that is both effective and safe.

3. Expanding Applications: Addiction, PTSD, OCD, and Bipolar Disorder

Beyond major depressive disorder, ketamine research has branched into multiple psychiatric conditions. For instance, small-scale and proof-of-concept studies suggest ketamine may alleviate symptoms of addiction by reducing drug cravings and withdrawal severity. [5] In post-traumatic stress disorder (PTSD), several open-label and randomized controlled trials have observed meaningful improvements in trauma-related symptoms following IV ketamine infusions. [6] Similarly, preliminary evidence indicates potential benefits in obsessive-compulsive disorder (OCD) and bipolar disorder, though replication studies with larger samples are required to establish clear clinical guidelines. [7][8][9]

4. Emergence of Esketamine (Spravato)

In 2019, the U.S. Food and Drug Administration (FDA) approved esketamine, a stereoisomer of ketamine, for TRD via intranasal administration. This formulation garnered significant attention as a “breakthrough” in mental health treatment—particularly because of its ease of use compared to IV administration. However, esketamine primarily targets the NMDA receptor and lacks arketamine, the other enantiomer in racemic ketamine, which has been shown to enhance antidepressant effects potentially through mechanisms involving the AMPA receptor. While short-term studies showed esketamine could reduce depressive symptoms, many researchers argue that esketamine’s long-term efficacy and safety remain less well-established compared to IV ketamine. Additionally, head-to-head data comparing the two in rigorous trials are limited. [10]

5. The High Cost of Esketamine

A major criticism of esketamine revolves around its price. Per-dose costs are substantially higher than those of racemic ketamine, making it less accessible for many patients without insurance coverage. This discrepancy is striking given that both forms require administration in a clinical setting under supervision to monitor potential dissociative or cardiovascular side effects. Despite the elevated drug cost, esketamine is often prioritized by insurance companies, creating an economic barrier for patients seeking IV ketamine, which actually provides greater efficacy.

The cost disparity is further exacerbated by the pharmaceutical backing of Janssen, the company that developed Spravato. Janssen’s marketing strategies and lobbying efforts have contributed to widespread insurance coverage of esketamine, even though IV ketamine is demonstrably cheaper on a per-dose basis and supported by extensive evidence. This situation underscores the influence of pharmaceutical companies in shaping treatment accessibility, potentially sidelining patient needs in favor of corporate profit motives. [11]

6. Big Pharma Influence and “Cost-Effectiveness”

An important factor in esketamine’s rise to prominence is the pharmaceutical backing from Janssen, the company that developed Spravato. Some analysts argue that Janssen’s lobbying efforts and marketing strategies have led insurers to view esketamine as the more “cost-effective” option, despite mounting evidence that racemic ketamine—particularly via IV administration—may be both cheaper and, for some patients, more effective. [12] A recent pharmacoeconomic analysis found that when factoring in the higher acquisition cost of esketamine, total expenditures can be significantly greater than with IV ketamine—unless insurance coverage artificially skews the out-of-pocket costs in favor of Spravato.

It is disgraceful that insurance companies fail to cover IV ketamine, a treatment backed by extensive research and lower costs, yet readily approve this Big Pharma-promoted alternative, prioritizing corporate interests over patient care. [13]

Furthermore, esketamine perpetuates a concerning model of mental health care that prioritizes pharmacological solutions over a comprehensive approach. This model often diminishes the critical role of psychotherapy and genuine patient-clinician connection, reducing mental health treatment to a medication-first strategy rather than integrating holistic care practices that address the underlying psychological and emotional needs of patients.

7. Looking Ahead

As research on ketamine’s broader psychiatric applications continues to expand, it is vital for clinicians, patients, and policymakers to examine the financial and regulatory structures that shape treatment availability. Esketamine’s FDA approval has undoubtedly made a rapid-acting antidepressant accessible to more patients, but it also serves as a stark example of Big Pharma leveraging patents to prioritize profits over patient care. By creating a costly product that offers limited advantages over the cheaper and well-researched IV ketamine, pharmaceutical companies like Janssen effectively inflate the overall cost of healthcare. This approach not only raises ethical concerns but also undermines efforts to provide equitable access to effective treatments. Future trials must compare these options directly, ensuring that evidence-based decisions prioritize clinical outcomes, patient affordability, and long-term safety over corporate interests.

---

References

[1] Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354.
[2] Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134-1142.
[3] Singh JB, Hughes A, Thompson E, et al. Intravenous ketamine in treatment-resistant depression: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2012;69(7):667-675.
[4] Correia-Melo FS, Silva SS, de Araújo CF, et al. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Psychiatr Res. 2022;146:134-141.
[5] Dakwar E, Levin F, Foltin RW, et al. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol Psychiatry. 2014;76(1):40-46.
[6] Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681-688.
[7] Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):2475-2483.
[8] Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939-946.
[9] Niciu MJ, Luckenbaugh DA, Ionescu DF, et al. Subanesthetic ketamine for unipolar major depressive disorder and bipolar depression: a systematic review and preliminary meta-analysis. J Affect Disord. 2014;168:448-515.
[10] Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-2). Am J Psychiatry. 2019;176(6):428-438.
[11] Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with an oral antidepressant in treatment-resistant depression (TRANSFORM-1): a randomized, double-blind, active-controlled study. Int J Neuropsychopharmacol. 2019;22(10):616-630.
[12] McIntyre RS, Rodrigues NB, Lee Y, et al. The effectiveness of intranasal esketamine in adults with treatment-resistant depression: A real-world, evidence-based, review. Eur Neuropsychopharmacol. 2021;48:80-93.
[13] Griswold M, Shinde A, Green G, et al. Pharmacoeconomic differences in management with SPRAVATO® vs. intravenous ketamine among commercial patients with major depressive disorder. J Affect Disord. 2022;320:495-503. doi:10.1016/j.jad.2022.10.046